Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?
Purpose This multicenter retrospective study assessed the real-world effectiveness and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis across eight centers in central Italy.Materials and methods A total of 150 patients received upadacitinib 15 mg or 30 mg daily as monother...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2509541 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849470018500165632 |
|---|---|
| author | Edoardo Mortato Niccolò Gori Giacomo Caldarola Marina Talamonti Claudia Paganini Luisa Boeti Filomena Russo Teresa Grieco Ersilia Tolino Gaia Moretta Flavia Pigliacelli Rosa Coppola Domenico Giordano Camilla Chello Concetta Potenza Maria Concetta Fargnoli Vincenzo Panasiti Barbara Cocuroccia Ketty Peris Marco Galluzzo |
| author_facet | Edoardo Mortato Niccolò Gori Giacomo Caldarola Marina Talamonti Claudia Paganini Luisa Boeti Filomena Russo Teresa Grieco Ersilia Tolino Gaia Moretta Flavia Pigliacelli Rosa Coppola Domenico Giordano Camilla Chello Concetta Potenza Maria Concetta Fargnoli Vincenzo Panasiti Barbara Cocuroccia Ketty Peris Marco Galluzzo |
| author_sort | Edoardo Mortato |
| collection | DOAJ |
| description | Purpose This multicenter retrospective study assessed the real-world effectiveness and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis across eight centers in central Italy.Materials and methods A total of 150 patients received upadacitinib 15 mg or 30 mg daily as monotherapy. Clinical outcomes were evaluated up to 104 weeks using Eczema Area and Severity Index (EASI), itch and sleep numeric rating scale (NRS), and Dermatology Life Quality Index (DLQI).Results Both dosages led to significant and sustained improvements in disease severity, pruritus, sleep disturbances, and quality of life, with 77.8% achieving EASI 75 and 39.2% achieving EASI 100 at week 16. Responses were similar between doses, although long-term itch control was better in the 30 mg group. Higher baseline EASI score was a positive predictor of response, while head and neck involvement and prior systemic treatments, particularly cyclosporine, were associated with poorer outcomes. The safety profile was consistent with prior reports, with acneiform eruption, elevated creatine phosphokinase (CPK), and dyslipidemia being the most common adverse events. No reactivation of atopic keratoconjunctivitis was observed.Conclusions These findings support the efficacy, safety, and flexibility of upadacitinib dosing in clinical practice. |
| format | Article |
| id | doaj-art-730b3a179da245b58735ec0deece2a0d |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-730b3a179da245b58735ec0deece2a0d2025-08-20T03:25:16ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2025.2509541Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?Edoardo Mortato0Niccolò Gori1Giacomo Caldarola2Marina Talamonti3Claudia Paganini4Luisa Boeti5Filomena Russo6Teresa Grieco7Ersilia Tolino8Gaia Moretta9Flavia Pigliacelli10Rosa Coppola11Domenico Giordano12Camilla Chello13Concetta Potenza14Maria Concetta Fargnoli15Vincenzo Panasiti16Barbara Cocuroccia17Ketty Peris18Marco Galluzzo19Department of Systems Medicine, University of Rome "Tor Vergata", Rome, ItalyDepartment of Translational Medicine and Surgery, Section of Dermatology, Catholic University of the Sacred Heart, Rome, ItalyDepartment of Translational Medicine and Surgery, Section of Dermatology, Catholic University of the Sacred Heart, Rome, ItalyDermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, ItalyDepartment of Systems Medicine, University of Rome "Tor Vergata", Rome, ItalyDepartment of Translational Medicine and Surgery, Section of Dermatology, Catholic University of the Sacred Heart, Rome, ItalyDepartment of Dermatology, Istituto Dermopatico dell’Immacolata IRCCS Roma, Rome, ItalyDepartment of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Dermatology Clinic, Sapienza University of Rome, Rome, ItalyDepartment of Medical and Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome-Polo Pontino, Latina, ItalyDepartment of Dermatology, Istituto Dermopatico dell’Immacolata IRCCS Roma, Rome, ItalySan Gallicano Dermatological Institute, IRCCS, Rome, ItalyOperative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, ItalyDepartment of Neurosciences, Mental Health and Sensory Organs, Sapienza University, Rome, ItalyDepartment of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Dermatology Clinic, Sapienza University of Rome, Rome, ItalyDepartment of Medical and Surgical Sciences and Biotechnologies, Dermatology Unit "D. Innocenzi", Sapienza University of Rome-Polo Pontino, Latina, ItalySan Gallicano Dermatological Institute, IRCCS, Rome, ItalyOperative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, ItalyDepartment of Dermatology, Istituto Dermopatico dell’Immacolata IRCCS Roma, Rome, ItalyDepartment of Translational Medicine and Surgery, Section of Dermatology, Catholic University of the Sacred Heart, Rome, ItalyDepartment of Systems Medicine, University of Rome "Tor Vergata", Rome, ItalyPurpose This multicenter retrospective study assessed the real-world effectiveness and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis across eight centers in central Italy.Materials and methods A total of 150 patients received upadacitinib 15 mg or 30 mg daily as monotherapy. Clinical outcomes were evaluated up to 104 weeks using Eczema Area and Severity Index (EASI), itch and sleep numeric rating scale (NRS), and Dermatology Life Quality Index (DLQI).Results Both dosages led to significant and sustained improvements in disease severity, pruritus, sleep disturbances, and quality of life, with 77.8% achieving EASI 75 and 39.2% achieving EASI 100 at week 16. Responses were similar between doses, although long-term itch control was better in the 30 mg group. Higher baseline EASI score was a positive predictor of response, while head and neck involvement and prior systemic treatments, particularly cyclosporine, were associated with poorer outcomes. The safety profile was consistent with prior reports, with acneiform eruption, elevated creatine phosphokinase (CPK), and dyslipidemia being the most common adverse events. No reactivation of atopic keratoconjunctivitis was observed.Conclusions These findings support the efficacy, safety, and flexibility of upadacitinib dosing in clinical practice.https://www.tandfonline.com/doi/10.1080/09546634.2025.2509541Upadacitinibatopic dermatitishead and neck dermatitisJAK inhibitors |
| spellingShingle | Edoardo Mortato Niccolò Gori Giacomo Caldarola Marina Talamonti Claudia Paganini Luisa Boeti Filomena Russo Teresa Grieco Ersilia Tolino Gaia Moretta Flavia Pigliacelli Rosa Coppola Domenico Giordano Camilla Chello Concetta Potenza Maria Concetta Fargnoli Vincenzo Panasiti Barbara Cocuroccia Ketty Peris Marco Galluzzo Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? Journal of Dermatological Treatment Upadacitinib atopic dermatitis head and neck dermatitis JAK inhibitors |
| title | Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? |
| title_full | Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? |
| title_fullStr | Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? |
| title_full_unstemmed | Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? |
| title_short | Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? |
| title_sort | use of upadacitinib in the treatment of moderate to severe atopic dermatitis patient profiling dose selection and therapy modulation what does real life teach us |
| topic | Upadacitinib atopic dermatitis head and neck dermatitis JAK inhibitors |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2025.2509541 |
| work_keys_str_mv | AT edoardomortato useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT niccologori useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT giacomocaldarola useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT marinatalamonti useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT claudiapaganini useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT luisaboeti useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT filomenarusso useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT teresagrieco useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT ersiliatolino useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT gaiamoretta useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT flaviapigliacelli useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT rosacoppola useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT domenicogiordano useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT camillachello useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT concettapotenza useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT mariaconcettafargnoli useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT vincenzopanasiti useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT barbaracocuroccia useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT kettyperis useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus AT marcogalluzzo useofupadacitinibinthetreatmentofmoderatetosevereatopicdermatitispatientprofilingdoseselectionandtherapymodulationwhatdoesreallifeteachus |